HUS2100053I1 - Interleukin-13-antitest-készítmény - Google Patents

Interleukin-13-antitest-készítmény

Info

Publication number: HUS2100053I1
Authority: HU; Hungary
Prior art keywords: interleukin; antibody preparation; antibody; preparation
Prior art date: 2005-09-30

Application number

HUS2100053C

Other languages

English (en)

Original Assignee

Medimmune Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-09-30

Filing date

2021-12-02

Publication date

2021-12-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37434894&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUS2100053(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-09-30 Priority claimed from GBGB0519923.7A external-priority patent/GB0519923D0/en

2021-12-02 Application filed by Medimmune Ltd filed Critical Medimmune Ltd

2021-12-28 Publication of HUS2100053I1 publication Critical patent/HUS2100053I1/hu

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
- A61K39/39525—Purification
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Mycology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Analytical Chemistry (AREA)
Inorganic Chemistry (AREA)
Endocrinology (AREA)
Hematology (AREA)
Oncology (AREA)
Otolaryngology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)

HUS2100053C 2005-09-30 2021-12-02 Interleukin-13-antitest-készítmény HUS2100053I1 (hu)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US72197405P	2005-09-30	2005-09-30
GBGB0519923.7A GB0519923D0 (en)	2005-09-30	2005-09-30	Interleukin-13 antibody composition
EP06794604.6A EP1942939B2 (en)	2005-09-30	2006-09-29	Interleukin-13 antibody composition
PCT/GB2006/003650 WO2007036745A2 (en)	2005-09-30	2006-09-29	Interleukin-13 antibody composition

Publications (1)

Publication Number	Publication Date
HUS2100053I1 true HUS2100053I1 (hu)	2021-12-28

Family

ID=37434894

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HUS2100053C HUS2100053I1 (hu)	2005-09-30	2021-12-02	Interleukin-13-antitest-készítmény

Country Status (20)

Country	Link
US (3)	US20080248048A1 (hu)
EP (1)	EP1942939B2 (hu)
JP (2)	JP2009510046A (hu)
KR (1)	KR101363777B1 (hu)
AU (1)	AU2006296399B2 (hu)
BR (1)	BRPI0616359B8 (hu)
CA (1)	CA2623429C (hu)
CY (2)	CY1120874T1 (hu)
FI (1)	FIC20210042I1 (hu)
FR (1)	FR21C1055I2 (hu)
GB (1)	GB2430883B (hu)
HU (1)	HUS2100053I1 (hu)
IL (3)	IL189983A (hu)
LT (1)	LTC1942939I2 (hu)
LU (1)	LUC00239I2 (hu)
NL (1)	NL301143I2 (hu)
NO (2)	NO344859B1 (hu)
PL (1)	PL1942939T5 (hu)
SI (1)	SI1942939T2 (hu)
WO (1)	WO2007036745A2 (hu)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8420086B2 (en) *	2002-12-13	2013-04-16	Immunomedics, Inc.	Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
ES2967485T3 (es)	2003-12-23	2024-04-30	Genentech Inc	Nuevos anticuerpos anti-IL 13 y usos de los mismos
MY144906A (en)	2005-10-21	2011-11-30	Novartis Ag	Human antibodies against il13 and therapeutic uses
SG170837A1 (en)	2006-04-05	2011-05-30	Abbott Biotech Ltd	Antibody purification
AR064826A1 (es) *	2007-01-09	2009-04-29	Wyeth Corp	Formulaciones de anticuerpos anti-il-13 y usos de los mismos. dispositivos, parche y jeringa
WO2009002521A2 (en) *	2007-06-25	2008-12-31	Amgen Inc.	Compositions of specific binding agents to hepatocyte growth factor
EP2173163A4 (en) *	2007-07-06	2010-12-08	Glaxosmithkline Llc	ANTIBODY FORMULATIONS
UA107557C2 (xx) *	2007-07-06	2015-01-26		Композиція антитіла офатумумабу
EP2050764A1 (en)	2007-10-15	2009-04-22	sanofi-aventis	Novel polyvalent bispecific antibody format and uses thereof
CN112481367A (zh)	2008-03-31	2021-03-12	健泰科生物技术公司	用于治疗和诊断哮喘的组合物和方法
GB0904214D0 (en)	2009-03-11	2009-04-22	Ucb Pharma Sa	Biological products
RS60577B1 (sr)	2009-10-20	2020-08-31	Abbvie Inc	Izolacija i prečišćavanje anti-il-13 antitela upotrebom protein a afinitetne hromatografije
TWI732259B (zh)	2010-12-16	2021-07-01	美商建南德克公司	關於th2抑制作用之診斷及治療
TWI700093B (zh)	2011-03-16	2020-08-01	法商賽諾菲公司	雙重ｖ區類抗體蛋白質之用途
EP2694708A4 (en) *	2011-04-07	2014-10-01	Glaxosmithkline Llc	FORMULATIONS WITH REDUCED VISCOSITY
HK1198328A1 (zh)	2011-07-13	2015-04-02	Abbvie Inc.	使用抗il-13抗體治療哮喘的方法和組合物
CA3078979C (en)	2011-10-31	2022-10-11	Genentech, Inc.	Formulation comprising an anti-il13 antibody having extended stability
HK1206796A1 (en)	2012-03-27	2016-01-15	F. Hoffmann-La Roche Ag	Methods of prognosing, diagnosing and treating idiopathic pulmonary fibrosis
UA117466C2 (uk)	2012-12-13	2018-08-10	Мерк Шарп Енд Доме Корп.	СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
US10023608B1 (en)	2013-03-13	2018-07-17	Amgen Inc.	Protein purification methods to remove impurities
JP6546178B2 (ja)	2013-09-13	2019-07-17	ジェネンテック，インコーポレイテッド	細胞株中の宿主細胞タンパク質及び組換えポリペプチド産物を検出及び定量化するための組成物並びに方法
EP4331605A3 (en)	2013-09-13	2024-05-22	F. Hoffmann-La Roche AG	Methods and compositions comprising purified recombinant polypeptides
SG11201603127WA (en)	2013-10-23	2016-05-30	Genentech Inc	Methods of diagnosing and treating eosinophilic disorders
JP2014062100A (ja) *	2013-11-05	2014-04-10	Glaxosmithkline Llc	抗体処方
CR20160379A (es)	2014-02-21	2016-10-07	Genentech Inc	Anticuerpos biespecificos anti-il 13/il-17 y sus usos
AU2015222755B2 (en) *	2014-02-27	2016-12-15	Board Of Regents, The University Of Texas System	Methods and compositions for isolating exosomes
US10066267B2 (en)	2014-04-11	2018-09-04	Novartis Ag	Methods of selectively treating asthma using IL-13 antagonists
AR103173A1 (es)	2014-12-22	2017-04-19	Novarits Ag	Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
JP6247241B2 (ja) *	2015-02-27	2017-12-13	ノバルティスアーゲー	抗体処方
MX2017011486A (es)	2015-03-16	2018-06-15	Genentech Inc	Métodos de detección y cuantificación de il-13 y sus usos en el diagnóstico y tratamiento de enfermedades asociadas a th2.
WO2017139290A1 (en) *	2016-02-10	2017-08-17	Medimmune, Llc	Tralokinumab delivery device
CN114617962A (zh)	2016-04-27	2022-06-14	艾伯维公司	使用抗-il-13抗体治疗il-13活性在其中有害的疾病的方法
ES2958593T3 (es)	2016-09-23	2024-02-12	Hoffmann La Roche	Usos de antagonistas de IL-13 para el tratamiento de la dermatitis atópica
JOP20190260A1 (ar)	2017-05-02	2019-10-31	Merck Sharp & Dohme	صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
WO2018204374A1 (en)	2017-05-02	2018-11-08	Merck Sharp & Dohme Corp.	Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
JP7418337B2 (ja)	2018-02-09	2024-01-19	ジェネンテック，インコーポレイテッド	マスト細胞媒介性炎症性疾患の治療法及び診断法
WO2020092015A1 (en)	2018-11-02	2020-05-07	University Of Rochester	Therapeutic mitigation of epithelial infection
BR112021008873A8 (pt)	2018-11-07	2023-04-11	Merck Sharp & Dohme	Formulação
JP2023534576A (ja)	2020-03-23	2023-08-10	メドイミューン・リミテッド	アトピー性皮膚炎及び関連する障害の治療方法
AU2020260519A1 (en)	2020-03-23	2021-10-07	Medimmune Limited	Methods for treating atopic dermatitis and related disorders
GB202108379D0 (en)	2021-06-11	2021-07-28	Medlmmune Ltd	Methods for treating a topic dermatitis and related disorders
TW202325731A (zh)	2021-08-16	2023-07-01	美商麥迪紐有限責任公司	抗ｉｌ—１３抗體調配物
CN118076636A (zh)	2021-09-15	2024-05-24	德米拉公司	Il-13抑制剂用于治疗结节性痒疹
EP4408885A1 (en)	2021-09-28	2024-08-07	MedImmune Limited	Methods for treating atopic dermatitis and related disorders
TW202544035A (zh)	2023-12-14	2025-11-16	美商德米拉股份有限公司	用於治療全年性過敏性鼻炎之il-13抗體
TW202541839A (zh)	2023-12-14	2025-11-01	美商德米拉股份有限公司	用於治療具鼻息肉之慢性鼻竇炎之il-13抗體
WO2025184453A1 (en)	2024-03-01	2025-09-04	Dermira, Inc.	Il-13 antibodies for the treatment of post-inflammatory hyperpigmentation or hypopigmentation of skin

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU217099B (hu)	1991-03-29	1999-11-29	Elf Sanofi Sa.	Eljárás citokin típusú aktivitással rendelkező fehérje, azt kódoló rekombináns DNS-szekvencia és a megfelelő transzformált sejtek és mikroorganizmusok előállítására
FR2685919B1 (fr) *	1992-01-08	1994-04-08	Elf Sanofi	Proteine a activite de type cytokine, adn recombinant codant pour cette proteine, cellules animales transformees.
US5596072A (en) *	1992-08-21	1997-01-21	Schering Corporation	Method of refolding human IL-13
JPH07267994A (ja) *	1994-03-31	1995-10-17	Snow Brand Milk Prod Co Ltd	新規蛋白質及びその製造法
JP3414856B2 (ja) *	1994-08-09	2003-06-09	株式会社ヤトロン	ジフェニルエーテル化合物の免疫学的測定方法
US5866154A (en) †	1994-10-07	1999-02-02	The Dupont Merck Pharmaceutical Company	Stabilized naloxone formulations
US6428788B1 (en) *	1995-03-15	2002-08-06	Penn State University	Compositions and methods for specifically targeting tumors
SK150298A3 (en) †	1996-05-04	1999-04-13	Zeneca Ltd	Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system
GB9610992D0 (en)	1996-05-24	1996-07-31	Glaxo Group Ltd	Concentrated antibody preparation
US6991790B1 (en)	1997-06-13	2006-01-31	Genentech, Inc.	Antibody formulation
WO1998056418A1 (en)	1997-06-13	1998-12-17	Genentech, Inc.	Stabilized antibody formulation
PL196770B1 (pl) †	1998-06-09	2008-01-31	Statens Seruminstitut	Sposób oczyszczania immunoglobuliny, produkt immunoglobuliny i jego zastosowanie
JP3537331B2 (ja) *	1998-11-17	2004-06-14	積水化学工業株式会社	Ｉｖ型コラーゲンの免疫測定法及び試薬
WO2001066754A1 (en) †	2000-03-03	2001-09-13	Cambridge Antibody Technology Limited	Human antibodies against eotaxin and their use
EP1175931A1 (en) †	2000-07-25	2002-01-30	Computer Cell Culture Center S.A.	Integration of high cell density bioreactor operation with ultra fast on-line downstream processing
WO2003010512A2 (en) †	2001-07-23	2003-02-06	Accurate Polymers, Inc.	High-speed, solid-liquid separation
JP2005512522A (ja) *	2001-10-26	2005-05-12	セントカー・インコーポレーテツド	Ｉｌ−１３ムテインタンパク質、抗体、組成物、方法および使用
US20040234499A1 (en)	2001-10-26	2004-11-25	David Shealy	Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses
US20030235555A1 (en)	2002-04-05	2003-12-25	David Shealey	Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses
US20040248260A1 (en)	2001-10-26	2004-12-09	Heavner George A.	IL-13 mutein proteins, antibodies, compositions, methods and uses
EP1551875A4 (en) *	2002-06-21	2006-06-28	Biogen Idec Inc	TAMPON PREPARATIONS FOR CONCENTRATING ANTIBODIES AND METHODS FOR USE THEREOF
PT1601697E (pt) †	2003-02-28	2007-09-04	Lonza Biologics Plc	Purificação de anticorpos através de proteína a e cromatografia de troca iónica.
EP1614693A4 (en) †	2003-03-31	2006-07-19	Kirin Brewery	Purification of a human monoclonal antibody and human polyclonal antibody
PL1610820T5 (pl) *	2003-04-04	2014-01-31	Genentech Inc	Preparaty zawierające wysokoskoncentrowane przeciwciała i białka
GB0407315D0 (en) *	2003-07-15	2004-05-05	Cambridge Antibody Tech	Human antibody molecules
TW200530269A (en) *	2003-12-12	2005-09-16	Chugai Pharmaceutical Co Ltd	Anti-Mpl antibodies
ES2967485T3 (es) *	2003-12-23	2024-04-30	Genentech Inc	Nuevos anticuerpos anti-IL 13 y usos de los mismos
CN1234725C (zh) †	2004-04-07	2006-01-04	陈志南	一种高效快速纯化制备片段抗体的方法
AR049390A1 (es) †	2004-06-09	2006-07-26	Wyeth Corp	Anticuerpos contra la interleuquina-13 humana y usos de los mismos
TWI307630B (en)	2004-07-01	2009-03-21	Glaxo Group Ltd	Immunoglobulins
CA2577631A1 (en) *	2004-08-20	2006-03-02	Amgen Inc.	Methods and compositions for treating allergic inflammation
EP1824886B1 (en) *	2004-11-17	2010-12-22	Amgen Inc.	Fully human monoclonal antibodies to il-13
US20060171943A1 (en) *	2005-02-01	2006-08-03	Amgen Inc.	Compositions and methods of treating fibrotic disorders
JP2013543028A (ja) †	2010-10-14	2013-11-28	ティコナゲゼルシャフトミットベシュレンクテルハフツング	可塑化ポリオキシメチレン

2006
- 2006-09-29 PL PL06794604T patent/PL1942939T5/pl unknown
- 2006-09-29 AU AU2006296399A patent/AU2006296399B2/en active Active
- 2006-09-29 GB GB0619204A patent/GB2430883B/en active Active
- 2006-09-29 EP EP06794604.6A patent/EP1942939B2/en active Active
- 2006-09-29 JP JP2008532878A patent/JP2009510046A/ja active Pending
- 2006-09-29 CA CA2623429A patent/CA2623429C/en not_active Expired - Fee Related
- 2006-09-29 US US12/067,120 patent/US20080248048A1/en not_active Abandoned
- 2006-09-29 SI SI200632277T patent/SI1942939T2/sl unknown
- 2006-09-29 BR BRPI0616359A patent/BRPI0616359B8/pt active IP Right Grant
- 2006-09-29 KR KR1020087010374A patent/KR101363777B1/ko active Active
- 2006-09-29 WO PCT/GB2006/003650 patent/WO2007036745A2/en not_active Ceased
2008
- 2008-03-06 IL IL189983A patent/IL189983A/en active IP Right Grant
- 2008-04-23 NO NO20081946A patent/NO344859B1/no active Protection Beyond IP Right Term
2010
- 2010-12-13 US US12/966,377 patent/US9107945B2/en active Active
2013
- 2013-10-10 JP JP2013212846A patent/JP5820450B2/ja active Active
- 2013-12-17 IL IL230005A patent/IL230005A/en active IP Right Grant
2015
- 2015-07-14 US US14/798,685 patent/US10358488B2/en active Active
2016
- 2016-07-10 IL IL246674A patent/IL246674B/en active IP Right Grant
2018
- 2018-07-20 CY CY181100758T patent/CY1120874T1/el unknown
2021
- 2021-11-03 NL NL301143C patent/NL301143I2/nl unknown
- 2021-11-05 CY CY2021033C patent/CY2021033I1/el unknown
- 2021-11-09 LU LU00239C patent/LUC00239I2/fr unknown
- 2021-11-12 NO NO2021050C patent/NO2021050I1/no unknown
- 2021-11-16 FR FR21C1055C patent/FR21C1055I2/fr active Active
- 2021-11-17 LT LTPA2021528C patent/LTC1942939I2/lt unknown
- 2021-11-23 FI FIC20210042C patent/FIC20210042I1/fi unknown
- 2021-12-02 HU HUS2100053C patent/HUS2100053I1/hu unknown

Also Published As

Publication number	Publication date
CY1120874T1 (el)	2019-12-11
NL301143I2 (nl)	2022-02-10
CY2021033I1 (el)	2022-03-24
CA2623429C (en)	2015-01-13
KR101363777B1 (ko)	2014-02-14
LTPA2021528I1 (hu)	2021-12-27
EP1942939B2 (en)	2021-07-07
IL230005A0 (en)	2014-01-30
CA2623429A1 (en)	2007-04-05
NO344859B1 (no)	2020-06-02
NO2021050I1 (no)	2021-11-12
GB0619204D0 (en)	2006-11-08
US20110086038A1 (en)	2011-04-14
PL1942939T5 (pl)	2021-10-11
EP1942939B1 (en)	2018-05-30
WO2007036745A3 (en)	2007-08-02
LTC1942939I2 (hu)	2023-10-10
US20160002327A1 (en)	2016-01-07
US20080248048A1 (en)	2008-10-09
SI1942939T2 (sl)	2021-11-30
AU2006296399A8 (en)	2008-07-17
US10358488B2 (en)	2019-07-23
GB2430883A (en)	2007-04-11
HK1210724A1 (en)	2016-05-06
IL189983A0 (en)	2008-08-07
US9107945B2 (en)	2015-08-18
IL246674A0 (en)	2016-08-31
IL189983A (en)	2016-11-30
IL230005A (en)	2016-05-31
JP5820450B2 (ja)	2015-11-24
AU2006296399B2 (en)	2011-01-20
JP2009510046A (ja)	2009-03-12
NO20081946L (no)	2008-06-27
AU2006296399A1 (en)	2007-04-05
EP1942939A2 (en)	2008-07-16
FR21C1055I1 (hu)	2021-12-24
LUC00239I2 (hu)	2025-02-03
JP2014040461A (ja)	2014-03-06
SI1942939T1 (sl)	2018-10-30
PL1942939T3 (pl)	2018-10-31
FIC20210042I1 (fi)	2021-11-23
WO2007036745A2 (en)	2007-04-05
KR20080054429A (ko)	2008-06-17
BRPI0616359B1 (pt)	2021-09-08
BRPI0616359B8 (pt)	2022-08-30
GB2430883B (en)	2008-03-19
FR21C1055I2 (fr)	2022-11-18
BRPI0616359A2 (pt)	2011-06-14
IL246674B (en)	2019-09-26
NL301143I1 (hu)	2021-11-10

Publication	Publication Date	Title
HUS2100053I1 (hu)	2021-12-28	Interleukin-13-antitest-készítmény
IL269201A (en)	2019-11-28	Glycosylated antibodies
LTPA2019520I1 (lt)	2019-11-11	Rekombinantiniai anti-IL-23 antikūnai
NO20076607L (no)	2008-02-27	TWEAK - bindende antistoff
DK1964852T3 (da)	2013-07-08	Anti-ilt7-antistof
HRP20150176T1 (xx)	2015-03-27	Protutijela protiv miostatina
NO20071430L (no)	2007-05-15	Anti-OX4OL antistoffer
LTPA2016026I1 (lt)	2016-09-26	Anti-il-17 antikūnai
PT1920065T (pt)	2018-12-04	Anticorpos anti-alfavbeta6 e suas utilizações
DE602006017373D1 (de)	2010-11-18	Madcam-antikörper
DK1853310T3 (da)	2012-10-22	Anti-Abeta-antistofpræparat
PT3620171T (pt)	2022-06-30	Anticorpos anti-gm-csf e suas utilizações
DK1771482T3 (da)	2014-10-20	HER2-antistofsammensætning
NO20071069L (no)	2007-02-26	Anti-CD154-antistoff
EP1765396A4 (en)	2008-07-02	ANTIBODY
EP1897558A4 (en)	2012-09-12	SOLID PREPARATION
NO20052035D0 (no)	2005-04-26	Stopemasse
PL1871804T3 (pl)	2014-01-31	Przeciwciała wiążące CCX-CKR2
SI1889059T1 (sl)	2009-12-31	IzboljĹˇani imunotestni postopek
DK1942939T4 (da)	2021-09-13	Interleukin-13-antistofsammensætning
FI7211U1 (fi)	2006-09-26	Sytytysmateriaali
ITVI20050002U1 (it)	2006-07-22	Sottovaso
FI20055336L (fi)	2006-12-23	Kuristin